Singapore, July 22 -- Tikva Allocell, a Singapore-based biotechnology startup developing engineered, allogeneic (donor-derived) cell therapies for adult and pediatric patients with solid tumours, has announced the closing of an $8 million Series A financing led by Kantharos Capital.

Proceeds will fund IND-enabling activities and a planned year-end 2026 Investigational New Drug (IND) submission for TAVST01, Tikva's lead candidate for B7-H3-positive solid tumours. Subject to regulatory clearance, the company plans to initiate a Phase 1 clinical trial in patients with advanced B7-H3-positive cancer at sites in Singapore and the United States.

TAVST01 targets B7-H3, a protein expressed across a broad range of difficult-to-treat solid tumors...